Evidence map›Paper›PMID 35668307›Full record

Trial reportAnnals of surgical oncology2022

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial).

Martha E Teke, Areeba Saif, Carrie E Ryan, Stephanie C Lux, Jonathan M Hernandez, Kim A Reiss

Abstract readLetterRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Pancreatic Cancer:Cancers · 2023
    Review
  5. PARP Inhibitors in Pancreatic Cancer.Cancer journal (Sudbury, Mass.)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Martha E TekeSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Areeba SaifSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Carrie E RyanSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Stephanie C LuxSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jonathan M HernandezSurgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. jonathan.hernandez@nih.gov.
Kim A ReissDepartment of Medicine, Abramson Cancer Center, Perelman Center for Advanced Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. kim.reissbinder@pennmedicine.upenn.edu.

Funding

Evaluating outcomes for patients with primary-metastatic gastrointestinal cancerZIABC011861 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HERNANDEZ, JONATHAN · 2019 to 2025
$166k
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pancreatic NeoplasmsPhthalazinesBRCA1 ProteinBRCA2 ProteinFanconi Anemia Complementation Group N ProteinGerm-Line MutationHumansMutationPiperazinesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanFanconi Anemia Complementation Group N ProteinolaparibPALB2 protein, humanPhthalazinesPiperazines

Identifiers

PMID35668307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.